Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 219-223

  Zhang, Hong ^a  

^a Z BioMed Inc   (United States)

Author keywords

Animal model; Influenza virus; Secondary bacterial pneumonia

Indexed keywords

ANTIVIRUS AGENT; GLYCOPEPTIDASE; HYBRID PROTEIN; RECOMBINANT ENZYME; RECOMBINANT SIALIDASE; SIALIC ACID; SIALIDASE;

AVIAN INFLUENZA; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CAUSE OF DEATH; CELL PROTECTION; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS A; MORTALITY; NONHUMAN; PANDEMIC; PATHOGENESIS; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; TARGET CELL; VIRUS CELL INTERACTION; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS STRAIN; VIRUS VIRULENCE;

BACTERIAL ADHESION; DISEASE SUSCEPTIBILITY; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PNEUMOCOCCAL INFECTIONS; RECOMBINANT FUSION PROTEINS;

EID: 47249148953     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn026     Document Type: Editorial

References (38)

1. Stephenson I, Nicholson KG. Influenza: Vaccination and treatment. Eur Respir J 2001; 17: 1282-93.
2. Zambon MC. The pathogenesis of influenza in humans. Rev Med Virol 2001; 11: 227-41.
3. Laver G, Garman E. Pandemic influenza: Its origin and control. Microbes Infect 2002; 4: 1309-16.
4. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362 1733-45.
5. McFee RB. Avian influenza: The next pandemic? Dis Mon 2007; 53 348-87.
6. World Health Organization. Pandemic preparedness. http://www.who.int/csr/disease/influenza/pandemic/en/index.html (20 November 2007, date last accessed).
7. World Health Organization. WHO Global Influenza Preparedness Plan. http://www.who.int/csr/resources/publications/influenza/ GIP_2005_5Eweb.pdf (20 November 2007, date last accessed).
8. World Health Organization. WHO National Influenza Pandemic Plans. http://www.who.int/csr/disease/influenza/nationalpandemic/en/index.html (20 November 2007, date last accessed).
9. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. http://www.who.int/csr/ disease/avian_influenza/country/cases_table_2007_11_12/en/index.html (20 November 2007, date last accessed).
10. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest 2006; 129: 156-68.
11. de Jone MD, Hien TT. Avian influenza A (H5N1). J Clin Virol 2006; 35: 2-13.
12. National Institute of Allergy and Infectious Diseases. Biodefense: NIAID Awards $212 Million to Advance Biodefense Therapeutics. http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/ funding/FY2006+Awards/therapeutic-awards.htm (20 November 2007, date last accessed).
13. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-9.
14. Bergelson LD, Bukrinskaya AG, Prokazova NV et al. Role of gangliosides in reception of influenza virus. Eur J Biochem 1982; 128: 467-74.
15. Griffin JA, Basak S, Compans RW. Effects of hexose starvation and the role of sialic acid in influenza virus release. Virology 1983; 125: 324-34.
16. van der Sluijs KF, van Elden LJ, Nijhuis M et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004; 172: 7603-9.
17. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods 2001; 94: 173-86.
18. Plotkowski MC, Puchelle E, Beck G et al. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134: 1040-4.
19. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187: 1000-9.
20. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190: 519-26.
21. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: Role of neuraminidase. Pediatr Infect Dis J 2004; 23 Suppl 1: S87-97.
22. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192: 249-57.
23. Seki M, Yanagihara K, Higashiyama Y et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004; 24: 143-9.
24. Seki M, Higashiyama Y, Tomono K et al. Acute infection with influenza virus enhances susceptibility to fatal pneumonia following Streptococcus pneumoniae infection in mice with chronic pulmonary colonization with Pseudomonas aeruginosa. Clin Exp Immunol 2004; 137: 35-40.
25. Giebink GS, Berzins IK, Marker SC et al. Experimental otitis media after nasal inoculation of Streptocoocus pneumoniae and influenza A virus in chinchillas. Infect Immun 1980; 30: 445-50.
26. Braun LE, Sutter DE, Eichellberger MC et al. Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus results in synergistic disease. Microb Pathog 2007; 43: 208-16.
27. Peltola VT, Boyd KL, McAuley JL et al. Bacterial sinusitis and otitis media following influenza virus infection in ferrets. Infect Immun 2006; 74: 2562-7.
28. Stray SJ, Cummings RD, Air GM. Influenza virus infection of desialylated cells. Glycobiology 2000; 10: 649-58.
29. Chu VC, Whittaker GR. Influenza virus entry and infection require host cell linked glycoprotein. Proc Natl Acad Sci USA 2004; 101: 18153-8.
30. Thompson CI, Barclay WS, Zambon MC et al. Infection of human airway epithelium by human and avian strains of influenza A virus. J Virol 2006; 80: 8060-8.
31. Kumari K, Gulati S, Smith DF et al. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 2007; 4: 42.
32. Olofsson S, Kumlin U, Dimock K et al. Avian influenza and sialic acid receptors: More than meets the eye? Lancet Infect Dis 2005; 5: 184-8.
33. Hardie W, Bokulic R, Garcia VF et al. Pneumococcal pleural empyemas in children. Clin Infect Dis 1996; 22: 1057-63.
34. Hardie WD, Roberts NE, Reising SF et al. Complicated para-pneumonic effusions in children caused by penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 1998; 101: 388-92.
35. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: A descriptive study. Chest 2001; 119: 1717-23.
36. Takayanagi N, Hara K, Tokunaga D et al. Clinical features and outcome in 84 patients with influenza pneumonia. Nihon Kokyuki Gakkai Zasshi 2006; 44: 681-8.
37. Bhatia A, Kast RE. How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett 2007; 12: 111-9.
38. Rennie P. Bowtell P, Hull D et al. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res 2007; 8: 38.